Martin Hossann is a chemist having received his training at the University of Kaiserslautern, Germany, where he also conducted his doctoral studies. He spent his postdoctoral studies at the University Hospital of the Ludwig-Maximilians-Universitaet Munich, Germany, with Lars Lindner and led the laboratory of the research group conducting basic and applied research on novel liposomal drug delivery technologies for over a decade.
He is the author/co-author of more than 15 scientific publications, primarily in the area of Thermosome’s TSL technology. During his academic research, he was instrumental in moving the basic scientific invention of a novel class of phospholipids towards an applicable drug delivery technology which can be leveraged for commercial drug development as a platform technology. Together with his team and collaborating academic research groups from various universities and countries comprising in peaks several dozen researchers, he moved the technology development from formulation development and characterization towards in vitro and in vivo testing, established crucial QA/QC processes and conducted extensive research in diverse areas with Thermosome’s TSL technology.